Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Dementia in 2010

Paving the way for Alzheimer disease drug development

Nature Reviews Neurology volume 7, pages 65–66 (2011)Cite this article

Subjects

Advances in Alzheimer disease (AD) research during 2010 have identified promising novel diagnostic tools and therapeutic targets for this condition, and suggest that amyloid-β immunotherapy reduces plaque load in patients with AD. A new lexicon for AD has also been proposed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Timeline of clinical definitions and criteria and developments in diagnostic biomarkers for AD.

References

  1. Fukumoto, H. et al. High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 24, 2716–2726 (2010).

    Article  CAS  PubMed Central  Google Scholar 

  2. Shankar, G. M. et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837–842 (2008).

    Article  CAS  PubMed Central  Google Scholar 

  3. He, G. et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467, 95–98 (2010).

    Article  CAS  PubMed Central  Google Scholar 

  4. Blennow, K., de Leon, M. J. & Zetterberg, H. Alzheimer's disease. Lancet 368, 387–403 (2006).

    Article  CAS  Google Scholar 

  5. Rinne, J. O. et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9, 363–372 (2010).

    Article  CAS  PubMed Central  Google Scholar 

  6. Hampel, H. et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 9, 560–574 (2010).

    Article  CAS  Google Scholar 

  7. Dubois, B. et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria. Lancet Neurol. 6, 734–746 (2007).

    Article  Google Scholar 

  8. Dubois, B. et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9, 1118–1127 (2010).

    Article  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Göteborgsvägen 31, SE-431 80, Mölndal, Sweden

    Kaj Blennow

Authors
  1. Kaj Blennow
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

K. Blennow has received honoraria from Janssen Alzheimer Immunotherapy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blennow, K. Paving the way for Alzheimer disease drug development. Nat Rev Neurol 7, 65–66 (2011). https://doi.org/10.1038/nrneurol.2010.214

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2010.214

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing